Nair, Unnikrishnan http://orcid.org/0000-0003-0894-5124
Gupta, Vishali
Sharma, Mohita
Joshi, Shrinivas
Sudhalkar, Aditya
Altangerel, Undraa
Bai, Yan
Agarwal, Manisha
Balakrishnan, Divya
Banker, Alay
Borse, Nishikant
Gupta, Vishali
Joshi, Shrinivas
Khatri, Manoj
Myneni, Jyotsna
Nagpal, Manish
Nair, Unnikrishnan
Rajesh, R.
Raval, Vishal R.
Reddy, Rajarami
Salhotra, Sudhir
Saswade, Manoj
Sharma, Mohita
Singh, Indu
Sinha, Anshuman
Sudhalkar, Aditya
,
Funding for this research was provided by:
Allergan (Not applicable)
Article History
Received: 16 July 2019
Accepted: 31 August 2020
First Online: 9 October 2020
Ethics approval and consent to participate
: Although IEC approval was obtained at 8 of the 19 investigator sites where there was a provision, IEC approval for this type of routine postmarketing surveillance study is not required per the country-specific requirements [CitationRef removed, CitationRef removed]. Signed written informed consent was obtained from all subjects who were included in the study at the baseline study visit.
: Not applicable.
: Financial arrangements of the authors with companies whose products may be related to the present report are listed below, as declared by the authors.Unnikrishnan Nair declares no competing interests.Vishali Gupta declares no competing interests.Mohita Sharma declares no competing interests.Shrinivas Joshi declares no competing interests.Aditya Sudhalkar declares no competing interests.Undraa Altangerel is an employee of AbbVie Inc.Yan Bai was an employee of Allergan plc during the conduct of the study.